NCT02287766|CompletedDMC
Metabolic Syndrome Feasibility Study
EPIC-009
Prognostic Indicators for Metabolic Syndrome as Provided by the EPIC ClearView
Loading search results
EPIC-009
Prognostic Indicators for Metabolic Syndrome as Provided by the EPIC ClearView
Sponsor study identifier
observational
193
1 country
2
Study Start
November 2014
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2015
Actual (reported)Study Completion
August 2015
Actual (reported)The objective of this study is to determine whether the finger tip images captured by the EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale that characterizes trends consistent with Metabolic Syndrome identified by medical doctors.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 2015
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 2014
Date type not reportedThis date has not been verified as actual or estimated.
November 5, 2014
Actual (reported)November 11, 2014
Actual (reported)June 2015
Actual (reported)August 2015
Actual (reported)Agreement of ClearView Scan versus Active Diagnosis
The EPIC ClearView software produces a Response Scale report that summarizes the electrophysiological measurements associated with organ systems. The autonomic numbers indicate how the person's stress response is affecting different body systems and the physical numbers reflect physiological function.These measurements will then be compared to metabolic diagnosis.
At time of ClearView Scan (Single study visit only, with no follow-up. The study endpoint will be reported for day 0, the day of the study visit
Sensitivity and Specificity of ClearView Scan versus Active Diagnosis
Single study visit only, with no follow-up. The study endpoint will be reported for day 0, the day of the study visit
Men and women ages 21-85 lacking any medical diagnosis (as defined in the protocol) of one or more of the following cancer, coronary artery disease or heart attack, renal failure or dialysis, hepatitis, Multiple Sclerosis, or any autoimmune disorder.
Men and women ages 21-85 with at least of at least three of the following (as defined in the protocol) : Elevated waist circumference, elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, elevated fasting glucose.
Men and women ages 21-85 who present to the investigators clinical office and meet all of the inclusion criteria while having none of the exclusion criteria will be approached for consent to participate in the study.
EPIC Research and Diagnostics
Scottsdale, Arizona, 85255, United States
Integrated Health Institute, LLC
Scottsdale, Arizona, 85255, United States
Nancy R Rizzo, PhD
EPIC Research and Diagnostics
193 participants (actual enrollment reported by the registry).
First Submitted
November 5, 2014
First Posted
November 11, 2014
Study Start
November 2014
Date type not reportedThis date has not been verified as actual or estimated.
Effects of TA-65, a Telomerase Activator on Metabolic Syndrome
Contact the study team to confirm eligibility.
Primary Completion
June 2015
Actual (reported)Study Completion
August 2015
Actual (reported)Last Updated
August 4, 2015
Record last verified: 2015-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: